Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Albuterol | 2 | 2004 | 26 | 0.470 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2004 | 92 | 0.460 |
Why?
|
| Asthma | 2 | 2004 | 345 | 0.350 |
Why?
|
| Ethanolamines | 2 | 2004 | 33 | 0.290 |
Why?
|
| Bronchodilator Agents | 2 | 2004 | 43 | 0.280 |
Why?
|
| Shock, Septic | 1 | 2006 | 101 | 0.270 |
Why?
|
| Clinical Protocols | 1 | 2006 | 172 | 0.260 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 261 | 0.240 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 438 | 0.230 |
Why?
|
| Private Sector | 1 | 2019 | 19 | 0.170 |
Why?
|
| Specialization | 1 | 2019 | 66 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2019 | 77 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2019 | 201 | 0.150 |
Why?
|
| Guanylate Cyclase | 1 | 2015 | 25 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 514 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 66 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 504 | 0.120 |
Why?
|
| Salmeterol Xinafoate | 2 | 2004 | 3 | 0.120 |
Why?
|
| Formoterol Fumarate | 2 | 2004 | 25 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2015 | 190 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2015 | 178 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2004 | 186 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 232 | 0.100 |
Why?
|
| Exercise Test | 1 | 2009 | 242 | 0.080 |
Why?
|
| Oxygen | 1 | 2009 | 386 | 0.070 |
Why?
|
| Walking | 1 | 2009 | 241 | 0.070 |
Why?
|
| Ketolides | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 207 | 0.070 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2006 | 32 | 0.070 |
Why?
|
| Polysomnography | 1 | 2006 | 92 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2006 | 131 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2006 | 142 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 187 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 649 | 0.050 |
Why?
|
| Humans | 8 | 2019 | 68618 | 0.050 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 1026 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 119 | 0.040 |
Why?
|
| Drug Costs | 1 | 2019 | 87 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 1615 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 622 | 0.030 |
Why?
|
| Time Factors | 1 | 2004 | 4655 | 0.030 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 84 | 0.030 |
Why?
|
| Middle Aged | 3 | 2019 | 21147 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 21403 | 0.020 |
Why?
|
| Prescriptions | 1 | 2009 | 28 | 0.020 |
Why?
|
| Male | 4 | 2019 | 37321 | 0.020 |
Why?
|
| Oximetry | 1 | 2009 | 29 | 0.020 |
Why?
|
| Female | 4 | 2019 | 38074 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5731 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5717 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 7277 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8912 | 0.020 |
Why?
|
| Fibromyalgia | 1 | 2006 | 29 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 164 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2077 | 0.010 |
Why?
|
| Aged | 2 | 2009 | 14862 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3705 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 1118 | 0.010 |
Why?
|
| Depression | 1 | 2006 | 943 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 1535 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7029 | 0.010 |
Why?
|
| Stroke | 1 | 2006 | 2163 | 0.010 |
Why?
|